Reply to "Letter to the Editor: Pitfalls in Calculating the Incidence of GBS During the Pandemic"

doi:10.1111/ene.70069

. 2025 Feb;32(2):e70069.

doi: 10.1111/ene.70069.

Reply to "Letter to the Editor: Pitfalls in Calculating the Incidence of GBS During the Pandemic"

Lorena Martín-Aguilar¹, Luis Querol^{1

2}

Affiliations

¹ Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
² Centro para la Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Barcelona, Spain.

PMID: 39931912
PMCID: PMC11811758
DOI: 10.1111/ene.70069

Reply to "Letter to the Editor: Pitfalls in Calculating the Incidence of GBS During the Pandemic"

Lorena Martín-Aguilar et al. Eur J Neurol. 2025 Feb.

. 2025 Feb;32(2):e70069.

doi: 10.1111/ene.70069.

Authors

Lorena Martín-Aguilar¹, Luis Querol^{1

2}

Affiliations

¹ Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
² Centro para la Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Barcelona, Spain.

PMID: 39931912
PMCID: PMC11811758
DOI: 10.1111/ene.70069

No abstract available

Keywords: COVID‐19; Guillain–Barré syndrome; Spain; epidemiology; vaccines.

PubMed Disclaimer

Conflict of interest statement

L.Q. received research grants from Instituto de Salud Carlos III—Ministry of Economy and Innovation (Spain), CIBERER, Fundació La Marató, GBS‐CIDP Foundation International, UCB and Grífols, received speaker or expert testimony honoraria from CSL Behring, Novartis, Sanofi‐Genzyme, Merck, Annexon, Alnylam, Biogen, Janssen, Lundbeck, ArgenX, UCB, LFB, Octapharma and Roche, serves at Clinical Trial Steering Committee for Sanofi‐Genzyme and Roche and is Principal Investigator for UCB’s CIDP01 trial. The other authors report no disclosures.

References

1. Keddie S., Pakpoor J., Mousele C., et al., “Epidemiological and Cohort Study Finds no Association Between COVID‐19 and Guillain‐Barré Syndrome,” Brain 144, no. 2 (2021): 682–693, 10.1093/brain/awaa433. - DOI - PMC - PubMed
1. Luijten L. W. G., Leonhard S. E., Van Der Eijk A. A., et al., “Guillain‐Barré Syndrome After SARS‐CoV‐2 Infection in an International Prospective Cohort Study,” Brain 144, no. 11 (2021): 3392–3404, 10.1093/brain/awab279. - DOI - PMC - PubMed
1. Censi S., Bisaccia G., Gallina S., Tomassini V., and Uncini A., “Guillain–Barré Syndrome and COVID‐19 Vaccination: A Systematic Review and Meta‐Analysis,” Journal of Neurology 271, no. 3 (2024): 1063–1071, 10.1007/s00415-024-12186-7. - DOI - PMC - PubMed
1. Abara W. E., Gee J., Marquez P., et al., “Reports of Guillain‐Barré Syndrome After COVID‐19 Vaccination in the United States,” JAMA Network Open 6, no. 2 (2023): 1–14, 10.1001/jamanetworkopen.2022.53845. - DOI - PMC - PubMed
1. Blanco‐Ruiz M., Martín‐Aguilar L., Caballero‐Ávila M., et al., “A Nationwide Guillain‐Barré Syndrome Epidemiological Study in Spain During the COVID‐19 Years,” medRxiv (2024), 10.1101/2024.03.27.24304897. - DOI - PMC - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources

[1] Keddie S., Pakpoor J., Mousele C., et al., “Epidemiological and Cohort Study Finds no Association Between COVID‐19 and Guillain‐Barré Syndrome,” Brain 144, no. 2 (2021): 682–693, 10.1093/brain/awaa433. - DOI - PMC - PubMed

[2] Keddie S., Pakpoor J., Mousele C., et al., “Epidemiological and Cohort Study Finds no Association Between COVID‐19 and Guillain‐Barré Syndrome,” Brain 144, no. 2 (2021): 682–693, 10.1093/brain/awaa433. - DOI - PMC - PubMed

[3] Luijten L. W. G., Leonhard S. E., Van Der Eijk A. A., et al., “Guillain‐Barré Syndrome After SARS‐CoV‐2 Infection in an International Prospective Cohort Study,” Brain 144, no. 11 (2021): 3392–3404, 10.1093/brain/awab279. - DOI - PMC - PubMed

[4] Luijten L. W. G., Leonhard S. E., Van Der Eijk A. A., et al., “Guillain‐Barré Syndrome After SARS‐CoV‐2 Infection in an International Prospective Cohort Study,” Brain 144, no. 11 (2021): 3392–3404, 10.1093/brain/awab279. - DOI - PMC - PubMed

[5] Censi S., Bisaccia G., Gallina S., Tomassini V., and Uncini A., “Guillain–Barré Syndrome and COVID‐19 Vaccination: A Systematic Review and Meta‐Analysis,” Journal of Neurology 271, no. 3 (2024): 1063–1071, 10.1007/s00415-024-12186-7. - DOI - PMC - PubMed

[6] Censi S., Bisaccia G., Gallina S., Tomassini V., and Uncini A., “Guillain–Barré Syndrome and COVID‐19 Vaccination: A Systematic Review and Meta‐Analysis,” Journal of Neurology 271, no. 3 (2024): 1063–1071, 10.1007/s00415-024-12186-7. - DOI - PMC - PubMed

[7] Abara W. E., Gee J., Marquez P., et al., “Reports of Guillain‐Barré Syndrome After COVID‐19 Vaccination in the United States,” JAMA Network Open 6, no. 2 (2023): 1–14, 10.1001/jamanetworkopen.2022.53845. - DOI - PMC - PubMed

[8] Abara W. E., Gee J., Marquez P., et al., “Reports of Guillain‐Barré Syndrome After COVID‐19 Vaccination in the United States,” JAMA Network Open 6, no. 2 (2023): 1–14, 10.1001/jamanetworkopen.2022.53845. - DOI - PMC - PubMed

[9] Blanco‐Ruiz M., Martín‐Aguilar L., Caballero‐Ávila M., et al., “A Nationwide Guillain‐Barré Syndrome Epidemiological Study in Spain During the COVID‐19 Years,” medRxiv (2024), 10.1101/2024.03.27.24304897. - DOI - PMC - PubMed

[10] Blanco‐Ruiz M., Martín‐Aguilar L., Caballero‐Ávila M., et al., “A Nationwide Guillain‐Barré Syndrome Epidemiological Study in Spain During the COVID‐19 Years,” medRxiv (2024), 10.1101/2024.03.27.24304897. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Reply to "Letter to the Editor: Pitfalls in Calculating the Incidence of GBS During the Pandemic"

Affiliations

Reply to "Letter to the Editor: Pitfalls in Calculating the Incidence of GBS During the Pandemic"

Authors

Affiliations

Conflict of interest statement

Similar articles

References

Publication types

LinkOut - more resources

Full Text Sources